Overview
Rare Diseases Regulatory Landscape
The regulatory environment for rare diseases therapies involves specialized requirements from FDA Office of Orphan Products Development, EMA Committee for Orphan Medicinal Products (COMP), PMDA Orphan Drug Division. This guide maps each requirement to ArcaScience's platform capabilities, demonstrating how AI-driven benefit-risk analysis aligns with and accelerates regulatory compliance.
Regulatory Requirements
Key Requirements by Agency
FDA Requirements
- ✓ Orphan Drug Act requirements and incentives
- ✓ Rare pediatric disease priority review voucher
- ✓ Accelerated approval for rare diseases
- ✓ Natural history study design guidance
- ✓ Post-marketing requirements for orphan drugs
EMA Requirements
- ✓ Orphan medicinal product designation criteria
- ✓ Guideline on clinical trials in small populations
- ✓ ATMP classification and BRA requirements
- ✓ Conditional marketing authorization for rare diseases
PMDA Requirements
- ✓ Japan orphan drug designation
- ✓ SAKIGAKE fast-track for rare diseases
- ✓ Conditional early approval for rare diseases
- ✓ Post-marketing surveillance obligations
ArcaScience Alignment
How ArcaScience Maps to Rare Diseases Requirements
Data Coverage
Rare Diseases-specific data from 47+ global sources, pre-harmonized and validated for regulatory submissions.
AI Models
Rare Diseases-trained AI models for adverse event classification, signal detection, and benefit quantification with regulatory validation.
Regulatory Outputs
Pre-formatted outputs aligned with FDA Office of Orphan Products Development and EMA Committee for Orphan Medicinal Products (COMP) submission requirements.
Download
Get the Full Rare Diseases Regulatory Landscape
Complete the form below to receive the document via email.
Related Resources